30 results
8-K
EX-99.1
EDIT
Editas Medicine, Inc.
3 Nov 23
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
7:06am
.
◦In October, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301 for the treatment of SCD
8-K
EX-99.1
w7agc0h3 i8zhz9ci2v6
28 Feb 19
Editas Medicine Announces Fourth Quarter and Full Year 2018 Results and Update
12:00am
8-K
ub4q0
7 Feb 19
Departure of Directors or Certain Officers
4:01pm
8-K
EX-99.2
ddv0k45dsxz
6 Aug 18
Editas Medicine Announces Second Quarter 2018 Results and Update
4:10pm